The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2017
Filed:
Jun. 09, 2015
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abbas W. Walji, Lansdale, PA (US);
Eric Hostetler, Collegeville, PA (US);
Thomas J. Greshock, Collegeville, PA (US);
Jing Li, Lansdale, PA (US);
Keith P. Moore, Doylestown, PA (US);
Idriss Bennacef, Ambler, PA (US);
James Mulhearn, Elkins, PA (US);
Harold Selnick, Ambler, PA (US);
Yaode Wang, Beijing, CN;
Kun Yang, Beijing, CN;
Jianmin Fu, Beijing, CN;
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.